Refine
Year of publication
Document Type
- Doctoral Thesis (23)
Has Fulltext
- yes (23)
Is part of the Bibliography
- no (23)
Keywords
- microRNA (3)
- Angiogenese (1)
- Blutgefäßsystem (1)
- Endothelzelle (1)
- Immunoseneszenz (1)
- Pulmonale Hypertonie (1)
- chronische Herzinsuffizienz (1)
- endothelial cell (1)
- glatte Gefäßmuskelzellen (1)
- miRNS (1)
- microRNA-17-92 cluster (1)
- pulmonary hypertension (1)
- smooth muscle cell (1)
Institute
- Biowissenschaften (11)
- Medizin (11)
- Biochemie und Chemie (1)
Almost two decades ago, microRNAs were discovered as novel posttranscriptional regulators of gene expression. Since then, research efforts have uncovered their involvement in the control of various cellular processes including migration, proliferation and cell survival. Even more complex events, such as the formation of new blood vessels or organ development, have been shown to be tightly regulated and orchestrated by microRNAs. Due to their crucial regulatory role in tissue homeostasis in vertebrates, it does not come as a big surprise that dysregulated microRNA ex-pression is associated with pathology of diverse diseases. In this regard, the miR-17-92 cluster is a prime example since it has become famous for its amplified expression in tumours and its on-cogenic potential. Our lab demonstrated the expression of the members of the miR-17-92 cluster, namely miR-17, -18a, -19a, -20a, -19b and -92a, in endothelial cells and provided evidence for the anti-angiogenic activity of miR-92a in ECs as well as its important regulatory role in tissue re-covery after ischemia. In this work we addressed the function of the remaining members of the miR-17-92 cluster, i.e. miR-17, miR-18a, miR-19a and miR-20a, in endothelial cells and angiogenesis. Surprisingly, the individual members all displayed anti-angiogenic properties in endothelial cells in vitro, although overexpression of the whole cluster in transformed colonocytes was shown to promote tumour angiogenesis in a mouse model. In this context, we provide evidence that the individual miRs differentially affect the paracrine angiogenic activity of endothelial and tumour cells. Moreover, Antagomir-mediated inhibition of miR-17/20 in a mouse tumour model did not affect tumour angi-ogenesis, although miR-17/20 inhibition profoundly increased vascularization of Matrigel plugs. Thus, our research efforts suggest a differential involvement of the members of the miR-17-92 cluster in physiological and tumour angiogenesis. Additionally, we identified Janus kinase (JAK) 1 as a novel miR-17 target in endothelial cells and demonstrated the involvement of JAK1 in angio-genesis and in the phosphorylation of STAT3 in response to different cytokines in vitro. Overall, inhibition of specific members of the miR-17-92 cluster might represent an attractive therapeutic strategy to enhance angiogenesis in ischemic diseases. In the second part of the present work we investigated the therapeutic value of Antagomir-mediated microRNA inhibition in animal models of pulmonary arterial hypertension. Collectively, inhibition of miR-17 by the respective Antagomir revealed a significant improvement of pulmonary hemodynamics and cardiac function in both the chronic hypoxia mouse model and the mono-crotaline-induced lung injury rat model. Histomorphometric analysis of the lungs of the pulmonary hypertensive mice and rats uncovered a significant reduction of disease associated musculariza-tion of pulmonary arteries in Antagomir-17 treated animals compared to the control animals indicating interference with smooth muscle cell proliferation or survival. Probing of lung tissue of the pulmonary hypertensive rats for selected miR-17 targets uncovered a profound increase in the expression of the cyclin dependent kinase inhibitor p21 in the Antagomir-17 treated rats suggest-ing that inhibition of miR-17 impairs proliferation by impeding cell cycle progression. Analysis of miR-17 function in human smooth muscle cells in vitro corroborated the results from the animal experiments by demonstrating pro-proliferative activity of miR-17 and decreased levels of p21 in these cells. Collectively, our results indicate that Antagomir-17 improves pulmonary hemodyna-mics and cardiac function by interfering with vascular remodelling within the lung. Hence, inhibi-tion of miR-17 might be of therapeutic value to ameliorate the disease pattern in pulmonary arte-rial hypertension. In summary, the present work provides insights into the regulatory functions of members of the miR-17-92 cluster, especially miR-17, in blood vessels and suggests that specific inhibition of members of the miR-17-92 cluster might be a novel option to treat vascular diseases.
ß1-integrins are essential for angiogenesis but the mechanisms regulating integrin function in endothelial cells (EC) and their contribution to angiogenesis remain elusive. BRAG2 is a guanine nucleotide exchange factor for the small Arf-GTPases Arf5 and Arf6. The role of BRAG2 in EC and angiogenesis and the underlying molecular mechanisms remains unclear. siRNA-mediated BRAG2-silencing reduced EC angiogenic sprouting and migration. BRAG2-siRNA-transfection differentially affected a5ß1- and aVß3-integrin function: specifically, BRAG2-silencing increased focal/fibrillar adhesions and EC adhesion on ß1-integrin-ligands (fibronectin and collagen), while reducing the adhesion on the aVß3-integrin-ligand, vitronectin. Consistent with these results, BRAG2-silencing enhanced surface expression of a5ß1-integrin, while reducing surface expression of aVß3-integrin. Mechanistically, BRAG2 mediated recycling of aVß3-integrins and endocytosis of ß1-integrins and specifically of the active/matrix bound a5ß1-integrin present in fibrillar/focal adhesions (FA), suggesting that BRAG2 contributes to the disassembly of FA via ß1-integrin-endocytosis. Arf5 and Arf6 are promoting downstream of BRAG2 angiogenic sprouting, ß1-integrin-endocytosis and the regulation of FA. In vivo silencing of the BRAG2-orthologues in zebrafish embryos using morpholinos perturbed vascular development. Furthermore, in vivo intravitral injection of plasmids containing BRAG2-shRNA reduced pathological ischemia-induced retinal and choroidal neovascularization. These data reveals that BRAG2 is essential for developmental and pathological angiogenesis by promoting EC sprouting through regulation of adhesion by mediating ß1-integrin internalization and associates for the first time the process of ß1-integrin endocytosis with angiogenesis.
Conclusion: Proteins containing a Jumonji C (JmjC) domain appear in almost all living organisms and catalyze a variety of oxidation reactions. Therefore, they are important regulators in many biological processes such as proliferation and differentiation. They act either as protein hydroxylases, histone demethylases or by regulate mRNA splicing. Given the fact that some of the JmjC domain-containing proteins are shown to be upregulated in response to hypoxia as well as the dependency of JmjC domain catalytic activity on oxygen led to the assumption of an involvement in angiogenesis. For Jmjd6, a member of the JmjC domain-containing protein family, a regulatory involvement in mRNA splicing has been shown. The Jmjd6-/- mouse dies perinatally due to several severe organ malformations, especially in the heart. Despite the pale appearance, the growth retardation and the cardiac defects, it is unclear whether these mice exhibit defects of cells comprising the vasculature. Therefore, the involvement of Jmjd6 in angiogenesis was examined in vitro using angiogenesis assays as well as in vivo using the Jmjd6+/- mouse. An siRNA-mediated knockdown of Jmjd6 in ECs significantly impaired the formation of capillary-like networks in the tube formation assay as well as sprouting in the spheroid assay. Moreover, after siRNA-mediated knockdown of Jmjd6 in ECs cell migration was significantly reduced. These findings were confirmed in the matrigel plug assay in vivo. Implanted matrigel plugs of Jmjd6+/- mice exhibited significantly less perfused vessels compared to wildtype littermates. Furthermore, cultured lung ECs from Jmjd6+/- mice exhibited impaired network forming activity ex vivo compared to cells isolated from wildtype littermates. To elucidate the mechanisms underlying the requirement of Jmjd6 in angiogenesis, an Affymetrix exon-array was performed, which allows detection of changes in gene expression as well as splicing. The siRNA-mediated knockdown of Jmjd6 altered the expression of genes known to play a role in vascular biology. The bioinformatic assessment of alternative splice variants revealed that Jmjd6 silencing affects the splicing of the VEGF receptor 1 (Flt1). Differential splicing of Flt1 was shown to generate a short and soluble form of Flt1 (sFlt1), which sequestrates VEGF and PlGF, and thereby inhibits angiogenesis. In particular, a significant increase in sFlt1 expression was observed. Jmjd6 was recently reported to hydroxylate the splicing factor U2AF65. Therefore, we investigated whether U2AF65 might mediate Flt1 splicing and binds to Flt1 mRNA. Indeed, U2AF65 co-immunoprecipitated with Jmjd6 in ECs, while an interaction of U2AF65 with sFlt1 was demonstrated. Moreover, inhibition of Jmjd6 catalytic function by reduced oxygen concentration altered splicing of Flt1 resulted in an increase of the sFlt1 splice variant. Finally, saturating concentrations of VEGF or PlGF or neutralizing antibodies against sFlt1 significantly reduced the inhibition of sprouting caused by Jmjd6 knockdown in vitro.
Collectively, our results indicate that Jmjd6 has an essential role in the oxygen-dependent regulation of angiogenesis by controlling the splicing of Flt1 mRNA, thereby adjusting the generation of the anti-angiogenic short splice variant sFlt1. Several publications demonstrated a major importance for sFlt1 as a biomarker for many severe human diseases such as preeclampsia, sepsis, cancer, myocardial infarction as well as chronic heart failure. Therefore, the identification of the molecular mechanism behind the generation of sFlt1 might enable the development of new or more precise clinical markers for the diagnosis of the corresponding diseases. Furthermore, the discovery of the enzymes involved in the generation of sFlt1 provides further possibilities to modulate sFlt1 levels and thereby may potentially gives rise to the development of new therapies.
Cardiovascular diseases are still regarded as the main cause of death in the modern world. However, the generic term "cardiovascular diseases" is not uniformly defined. It essentially describes diseases of the cardiovascular system and includes diseases such as hypertension, arteriosclerosis, myocardial infarctions, heart failure, coronary heart diseases, rheumatic heart diseases and heart valve defects. In addition to the well-known risk factors such as obesity, smoking, hypercholesterolemia and lack of exercise, age is a further risk factor that plays an important role in the development of cardiovascular diseases. As the modern societies age; this becomes an increasing problem.
But why does the prevalence of cardiovascular diseases increase with age? In gen-eral, age-dependent changes at the cellular level are assumed to be responsible for the pathological changes in the cardiac and vascular tissues. Important mechanisms such as autophagy, oxidative stress, mitochondrial dysfunctions, genomic instability, cellular senescence and disturbances in signaling pathways of growth factors play a decisive role. In old age, myocardial hypertrophy occurs, which results in cardiac wall thickening and an altered geometry of the ventricle. Chronic inflammations, paracrine and age-dependent cell-intrinsic factors further lead to activation of cardiac fibro-blasts with increase cell proliferation, collagen secretion and matrix cross-linking. The consequences are interstitial and perivascular fibrosis, which stiffen the heart and blood vessels. Oxidative stress and inflammations additionally attack the blood ves-sels and impair endothelial function, which is further aggravated by possible pre-existing conditions such as diabetes mellitus and hypertension.
In the past decades, the main focus has therefore been on researching these age-dependent changes in the hope of better understanding cardiovascular ageing and developing possible regenerative interventions. By studying the repair mechanisms of other organs such as the lungs and the bone marrow, the endothelium in particular showed a high regenerative capacity, which influences the proliferation and cell func-tion of the surrounding cells.
For a long time, the general opinion was that the endothelium is only the internal lin-ing of blood and lymphatic vessels, as well as the heart chambers, which as a single-layer barrier guarantees the integrity of the blood vessels. However, endothelial cells are very heterogeneous, depending on the type of blood vessel and the type of tis-sue they serve. In addition to their barrier function, endothelial cells also regulate the exchange of substances between blood and tissue, stimulate the formation of new blood vessels and re-model existing vascular networks. They are also able to re-structure the extracellular matrix that surrounds them. They release not only matrix proteins, but also cytokines and growth factors into the extracellular space. On de-mand, these factors are then released and stimulate angiogenesis or cell prolifera-tion. In addition, the secretion of various matrix proteins not only stabilizes the cellu-lar neighborhood, but also regulates various cell functions.
By modelling the endothelial environment - the so-called vascular niche - endothelial cells are able to communicate with the surrounding cells. As a result, a regenerative effect of the vascular niche has already been described in various organs. In the liv-er, for example, it has been shown that increased concentrations of endothelial Ang2 and decreased endothelial activin A after partial hepatectomy stimulate the prolifera-tion of hepatocytes and thus liver regeneration. In the bone marrow, endothelial cells mobilize stem cells via nitric oxide and in the lungs, endothelial MMP14 releases growth factors from the extracellular matrix, which stimulate epithelial cell prolifera-tion after partial pneumectomy. Whether such a regenerative effect of the vascular niche also plays a role in the heart is largely unknown.
Since both the regenerative capacity of the heart and endothelial function decrease with age, the aim of this dissertation was to investigate the role of the vascular niche and endothelial cell communication in the aged heart. Human cell lines as well as mouse and artificial rat models were used for these investigations. Since this thesis is a cumulative dissertation with partially published papers, it is divided into three parts.
In the first part of this thesis, the transcriptional signature of secretory genes in the aged cardiac endothelium was studied. Perfused endothelial cells from hearts of young (12-week-old animals) and old mice (20-month-old animals) were isolated and used for bulk RNA sequencing. The two matrix proteins laminin β1 and β2 were among the top-regulated genes. While laminin β2 was particularly expressed in the young cardiac endothelium, laminin β1 was predominantly found in the old endotheli-um. This change in laminin expression was confirmed histologically at protein level and its autocrine function was investigated in vitro. To mimic the in vivo situation in vitro, cell culture dishes were coated with human recombinant laminin 421 or laminin 411 and sutured with human endothelial cells from the umbilical vein (HUVEC). Di-verse functional investigations showed that endothelial cells migrated and adhered poorly in the presence of laminin 411, while in Matrigel tube formation assays HU-VEC formed reduced endothelial networks when cultured on LM 411.
...
One of the key functions of blood vessels is to transport nutrients and oxygen to distant tissues and organs in the body. When blood supply is insufficient, new vessels form to meet the metabolic tissue demands and to re-establish cellular homeostasis. Expansion of the vascular network through sprouting angiogenesis requires the specification of ECs into leading (sprouting) tip and following (non-sprouting) stalk cells. Attracted by guidance cues tip cells dynamically extend and retract filopodia to navigate the nascent vessel sprout, whereas trailing stalk cells proliferate to form the extending vascular tube. All of these processes are under the control of environmental signals (e.g. hypoxia, metabolism) and numerous cytokines and peptide growth factors. The Dll4/Notch pathway coordinates several critical steps of angiogenic blood vessel growth. Even subtle alterations in Notch activity can profoundly influence endothelial cell behavior and blood vessel formation, yet little is known about the intrinsic regulation and dynamics of Notch signaling in endothelial cells. In addition, it remains an open question, how different growth factor signals impinging on sprouting ECs are coordinated with local environmental cues originating from nutrient-deprived, hypoxic tissue to achieve a balanced endothelial cell response. Acetylation of lysines is a critical posttranslational modification of histones, which acts as an important regulatory mechanism to control chromatin structure and gene transcription. In addition to histones, several non-histone proteins are targeted for acetylation reversible acetylation is emerging as a fundamental regulatory mechanism to control protein function, interaction and stability. Previous studies from our group identified the NAD+-dependent deacetylase SIRT1 as a key regulator of blood vessel growth controlling endothelial angiogenic responses. These studies revealed that SIRT1 is highly expressed in the vascular endothelium during blood vessel development, where it controls the angiogenic activity of endothelial cells. Moreover, in this work SIRT1 has been shown to control the activity of key regulators of cardiovascular homeostasis such as eNOS, Foxo1 and p53. The present study describes that SIRT1 antagonizes Notch signaling by deacetylating the Notch intracellular domain (NICD). We showed that loss of SIRT1 enhances DLL4-induced endothelial Notch responses as assessed by different luciferase responsive elements as well as transcriptional analysis of Notch endogenous target genes activation. Conversely, SIRT1 gain of function by overexpression of pharmacological activation decreases induction of Notch targets in response to DLL4 stimulation. We also showed that the NICD can be directly acetylated by PC AF and p300 and that SIRT1 promotes deacetylation of NICD. We have identified 14 lysines that are targeted for acetylation and their mutation abolishes the effects of SIRT1 of Notch responses. Furthermore, over-expression or activation of SIRT1 significantly reduces the levels of NICD protein. Moreover, SIRT1-mediated NICD degradation can be reversed by blockade of the proteasome suggesting a mechanism resulting from ubiquitin-mediated proteolysis. Indeed, we have shown that SIRT1 knockdown or pharmacological inhibition decreased NICD ubiquitination. We propose a novel molecular mechanism of modulation of the amplitude and duration of Notch responses in which acetylation increases NICD stability and therefore permanence at the promoters, while SIRT1, by inducing NICD degradation through its deacetylation, shortens Notch responses. In order to evaluate the physiological relevance of our findings we used different models in which the Notch functions during blood vessel formation have been extensively characterized. First, retinal angiogenesis in mice lacking SIRT1 activity shows decreased branching and reduced endothelial proliferation, similar to what happens after Notch gain of function mutations. ECs from these mice exhibit increased expression of Notch target genes. Second, these results were reproducible during intersomitic vessel growth in sirt1-deficient zebrafish. In both models, the defects could be partially rescued by inhibition of Notch activation. Third, we used an in vitro model of vessel sprouting from differentiating embryonic bodies in response to VEGF in a collagen matrix. Our results showed that Sirt1-deficient cells shows impaired sprouting which correlated with increased NICD levels. In addition, when in competition with wild-type cells in this assay, Sirt1-deficient cells are more prone to occupy the stalk cell position. Taken together, our study identifies reversible acetylation of NICD as a novel molecular mechanism to adapt the dynamics of Notch signaling and suggest that SIRT1 acts as a rheostat to fine-tune endothelial Notch responses. The NAD+-dependent feature of SIRT1 activity possibly links endothelial Notch responses to environmental cues and metabolic changes during nutrient deprivation in ischemic environments or upon other cellular stresses.
Cardiovascular disease is the leading cause of death worldwide. Aging is among the greatest risk factors for cardiovascular disease. Cardiovascular disease comprises several diseases, for example myocardial infarction, elevated blood pressure and stroke. Many processes are known to promote or worsen cardiovascular disease and in the present study, cellular senescence and inflammatory activation were of special interest, as they have a strong association to aging and can be seen as hallmarks of cellular aging.
Long noncoding RNAs (lncRNAs) are noncoding RNAs with a length of more than 200 nucleotides. In recent years, numerous regulatory functions were shown for these transcripts and lncRNAs were shown to directly interact with DNA, RNA and proteins. The long noncoding RNA H19 was among the first described noncoding RNAs and was initially shown to act as a tumor suppressor. More recently, several studies showed oncogenic roles for H19. In regards to the cardiovascular system, H19 was not analyzed before.
We show that H19 is the most profoundly downregulated lncRNA in endothelial cells of aged mice compared to young littermates. Microarray analysis of human primary endothelial cells upon pharmacological H19 depletion revealed an involvement of H19 in cell cycle regulation. Loss of H19 in human endothelial cells in vitro led to reduced proliferation and to increased senescence. H19 depletion was shown to counteract proliferation before, but none of the described mechanisms applied to endothelial cells. We show that the reduction in proliferative capacity and the pro-senescent function of H19 is most probably mediated by an upregulation of p16ink4A and p21 upon H19 depletion.
When we compared the angiogenic capacity of aortic endothelial cells from young and aged mice in an aortic ring assay, rings from aged mice showed a reduced cumulative sprout length. Interestingly, pharmacological inhibition of H19 in aortic rings of young animals, where H19 is highly expressed, was sufficient to reduce the cumulative sprout length to levels we observed from aged animals. Furthermore, overexpression of human H19 in aortic rings of aged mice, where H19 is poorly expressed, rescued the impaired angiogenic capacity of aged endothelial cells.
We generated inducible endothelial-specific H19 knockout mice (H19iEC-KO) and subjected these animals to hind limb ischemia surgery followed by perfusion analysis in the hind limbs by laser-doppler velocimetry and histological analysis. Perfusion in the operated hind limb was increased in H19iEC-KO compared to Ctrl littermates, which was in contrast to a reduction in capillary density in the operated hind limbs of H19iEC-KO animals compared to Ctrl littermates and to our previous results. Analysis of arteriogenesis revealed an increase in collateral growth upon EC-specific H19 depletion in the ischemic hind limbs, which explains the increase in perfusion despite the reduction in capillary density. Further characterization of the animals revealed an increase in leukocyte infiltration into the tissue in the ischemic hind limbs upon endothelial-specific H19 depletion, indicating a potential role of H19 in inflammatory tissue activation.
Reanalysis of the microarray data from human primary endothelial cells upon H19 depletion revealed an association of H19 with inflammatory signaling and more specifically with IL-6/JAK2/STAT3 signaling. Analysis of cell surface adhesion molecule expression revealed an upregulation of ICAM-1 and VCAM-1 on mRNA level and an increase of the abundance of the two proteins on the cell surface of human primary endothelial cells. Consequently, adhesion of isolated human monocytes to human primary endothelial cells was increased upon H19 depletion in vitro. Interestingly, TNF-α mediated inflammatory activation of primary human endothelial cells repressed H19 expression. H19 did not function via previously described mechanisms. We excluded a competitive endogenous RNA (ceRNA) function for H19 in endothelial cells and showed that miR-675, which is processed from H19, does not play a role in the endothelium. Furthermore, H19 did not regulate previously described genes or pathways.
Analysis of transcription factor activity upon H19 depletion and overexpression revealed a differential activity of STAT3. STAT3 phosphorylation at TYR705 and thus activation was increased upon H19 depletion. Inhibition of STAT3 activation using a small compound inhibitor abolished the effects of H19 depletion on mRNA expression of p21, ICAM-1 and VCAM-1 and on proliferation, indicating that the effects of H19 are at least partially mediated via STAT3. STAT3 was shown to have positive effects on the cardiovascular system before, most likely due to upregulation of VEGF in a STAT3-dependent manner. We were not able to confirm previously described mechanisms for STAT3 in the present study and propose a new mechanism of action for the H19-dependent regulation of STAT3. Taken together, these results identify the long noncoding RNA H19 as a pivotal regulator of endothelial cell function. Figure 38 summarizes the described functions of H19 in endothelial cells.
Flow hemodynamics regulates endothelial cell (EC) responses and laminar shear stress induces an atheroprotective and quiescent phenotype. The flow-responsive transcription factor KLF2 is a pivotal mediator of endothelial quiescence, but the precise mechanism is unclear. In this doctoral study, we assessed the hypothesis that laminar shear stress and KLF2 regulate endothelial quiescence by controlling endothelial metabolism.
Laminar flow exposure and KLF2 over expression in HUVECs reduced glucose uptake. Endothelial specific deletion of KLF2 (EC-KO) in mice and subsequent infusion of labeled glucose in Langendorff perfused hearts induced glucose uptake in ECs lacking KLF2. Bioenergetic measurements revealed that KLF2 reduces and glycolytic acidification in vitro.
Mechanistically, RNA sequencing analysis of shear stimulated ECs showed reduced expression of key glycolytic enzymes Hexokinase 2, PFKFB3 and PFK-1. KLF2 also reduced expression of these enzymes at protein level. KLF2 knockdown in shear stimulated ECs reversed the reduction in expression of PFKFB3 and PFK-1, indicating KLF2-dependency. Promoter analysis revealed KLF binding sites in the promoter of PFKFB3 and KLF2 over expression markedly reduced PFKFB3 promoter activity which was abolished on mutation of the KLF binding site. In addition, PFKFB3 knockdown reduced glycolysis while over expression increased glycolysis. Over expression of PFKFB3 along with KLF2 partially reversed the KLF2-mediated reduction in glycolysis. Importantly, PFKFB3 over expression reversed KLF2-mediated reduction in angiogenic sprouting and network formation in vitro. Ex-vivo aortic ring assays revealed an increase in endothelial sprouting from aortas from KLF2 EC-KO mice, which was partially reversed upon PFKFB3 inhibition by 3-PO.
In conclusion, work performed during this doctoral thesis demonstrates that laminar shear stress and KLF2 mediated repression of endothelial metabolism via regulation of PFKFB3 contributes to the anti-angiogenic and quiescent properties of the endothelium.
Chronische Herzinsuffizienz ist eine der führenden Todesursachen im Rahmen kardiovaskulärer Erkrankungen und ist mit einer hohen Anzahl an Komorbiditäten assoziiert. Unter anderem führt Herzinsuffizienz zu Veränderungen des Immunsystems, welche denen der Immunoseneszenz ähneln. Als einflussreiche Modulatoren ganzer molekularbiologischer Regelkreise sind microRNAs in den letzten Jahren zunehmend in den Fokus gerückt. Diese nicht-kodierenden, kurzen RNA-Einzelstränge können die Genexpression von vielen Zielgenen durch spezifisches Binden der jeweiligen mRNA Transkripte kontrollieren. Aufgrund zum Teil gewebe-, zelltyp- und prozess-spezifischer Expression können microRNAs auch als mögliche Biomarker für spezifische klinische Fragestellungen dienen.
Im Rahmen der vorliegenden Arbeit wurde die Expression von immunmodulatorischen microRNAs im peripheren Blut (PB) von jungen und gealterten gesunden Probanden (y/h bzw. o/h) sowie Patienten mit chronischer Herzinsuffizienz (CHF) untersucht. Dabei wurde ein Bezug auf Immunoseneszenz bzw. die Auswirkung von CHF auf das Immunsystem hergestellt. Im Rahmen dessen wurden Leukozyten-, insbesondere Lymphozyten-Subpopulationen analysiert.
Hierzu wurden Probanden in die drei folgenden Gruppen eingeschlossen: Patienten mit CHF (n=18, durchschnittliches Alter 64 Jahre), alters-korrelierte gesunde Probanden (n=13, durchschnittliches Alter 64 Jahre) sowie junge gesunde Probanden (n=30, durchschnittliches Alter 25 Jahre). Neben der Erhebung der klinischen Daten wurde peripheres Blut zur Bestimmung der microRNA-Expressionslevels sowie für durchflusszytometrische Analysen der Leukozytenpopulationen gewonnen.
In den Expressionsanalysen konnte eine alters- und herzinsuffizienz-abhängige Dysregulation einzelner microRNAs beobachtet werden. Insbesondere Mitglieder der miR-181-Familie, spezifisch miR-181a und miR-181c, waren im Alter niedriger exprimiert, zudem war die Expression von miR-181c bei Vorliegen einer CHF deutlicher reduziert. Des Weiteren zeigte sich eine altersabhängige erhöhte Expression von miR-34a, wobei das Vorliegen von CHF keine Auswirkung auf die Expression zeigte. Bei den microRNAs miR-146a und miR-223 konnte keine signifikante alters- oder CHF-abhängige Regulation nachgewiesen werden. Lediglich zeigte bei der miR-155 zeigte sich eine signifikante Reduktion bei Vorliegen einer CHF im Vergleich o/h Probanden.
In Hinblick auf die Leukozytenpopulationen im peripheren Blut wiesen Patienten mit CHF höhere Zahlen an Leukozyten auf, alle miR-181 Mitglieder zeigten hierbei eine inverse Korrelation. Dagegen stellte sich in Hinblick auf die Zusammensetzung der Leukozyten-Subpopulationen eine Reduktion der Lymphozytenfraktion im Alter dar, besonders bei Patienten mit CHF. Insbesondere zeigte sich eine altersabhängige Abnahme der B-Lymphozytenpopulation, wobei auch hier das Vorliegen einer CHF diesen Effekt verstärkte. Die Expression miR-181a und miR-181c sowie miR-146a und miR-223 korrelierte positiv mit dem Anteil der B-Lymphozyten. Innerhalb der B-Zellen zeigte sich eine alters- und CHF-abhängige Reduktion der naïven B-Zellen, welche positiv mit der Expression von miR-181c, miR-146a und miR-223 korrelierte. Die beobachteten Veränderungen der B-Zell-Subpopulationen zeigten sich insbesondere bei CHF Patienten mit ischämischer Ursache im Vergleich zur dilatativen Kardiomyopathie.
Bei den untersuchten T-Lymphozyten-Subpopulationen zeigte sich eine altersabhängiger Abfall bei den zytotoxischen T-Zellen. Das Vorliegen einer CHF verstärkte diesen Effekt. Die beobachteten Veränderungen der T-Zell-Subpopulation korrelierten nicht mit der Expression der untersuchten microRNAs.
Im Gegensatz zu den lymphoiden Subpopulationen zeigte sich ein Anstieg der neutrophilen Granulozyten und der Monozyten im Alter, es stellte sich jeweils eine negative Korrelation mit der Expression von miR-181 Transkripten sowie miR-155, miR-146a und miR-223 dar.
Zusammenfassend zeigten sich signifikant erniedrigte Expressionslevels von miR-181c im Alter, was mit Immunoseneszenz-bedingten Veränderungen des peripheren Bluts einherging. Diese Veränderungen zeigten sich zusätzlich verstärkt bei Patienten mit CHF. Zukünftig könnten miR-181c Expressionslevel in peripherem Blut als Biomarker für die Immunfunktionen bei CHF Patienten dienen und in Hinblick auf eine mögliche prospektive Information evaluiert werden.
Cardiovascular diseases are a leading cause of morbidity and mortality worldwide. Aging inflicts structural and molecular changes on the heart that oftentimes involve ischemic events, cardiomyocyte apoptosis and cardiac stiffening, which makes it a major risk factor for cardiovascular disease. After being disregarded as transcriptional noise for a long time, long non-coding RNAs have lately emerged as key regulators of many cellular processes in physiology and disease of virtually all tissues and organs, with some of them being differentially regulated during aging.
This study identified a long non-coding transcript antisense to the OXCT1 gene locus, Sarrah, to be downregulated in the heart during aging, after acute myocardial infarction and upon heart failure with preserved ejection fraction. Sarrah is expressed in several cardiac cell types with highest levels in cardiomyocytes, where it is predominantly localized in the nucleus. In mouse and human cardiomyocytes, Sarrah levels are reduced upon exposure to hypoxia or treatment with hypoxiamimetic agents in vitro.
Sarrah exerts an anti-apoptotic function in mouse and human cardiomyocytes as assessed from caspase activity and annexin V staining. Histological stainings of Sarrah-depleted human engineered heart tissue organoids and Sarrah overexpressing infarcted mouse hearts confirmed its anti-apoptotic function. Sarrah also plays a role in cardiomyocyte contractility, which is substantially impaired upon Sarrah silencing in human engineered heart tissue and neonatal rat cardiomyocytes. Additionally, cardiomyocytal Sarrah stimulates endothelial cell proliferation via paracrine effects as observed after Sarrah overexpression in mouse hearts as well as in co-culture settings with human endothelial cells and Sarrah-depleted or Sarrah overexpressing human cardiomyocytes. A microarray analysis revealed that silencing Sarrah in human cardiomyocytes induced apoptosisrelated gene expression. Mechanistically, Sarrah was predicted to form triplexes in human and mouse with promoters of genes downregulated, but not upregulated after Sarrah knockdown, suggesting that Sarrah interacts with target genes to activate their transcription. This interaction was confirmed in vitro using nucleic acid oligonucleotides containing the sequences of the Sarrah triplex motif and the Sarrah binding site of the exemplary target gene GPC6 of both human and mouse. RNA immunoprecipitation experiments in human cells demonstrated that Sarrah is associated with open chromatin, transcription factor CRIP2, transcriptional co-activator p300 and DNA-RNA hybrid structures that also occur in Sarrah target gene promoters, which indicated that Sarrah activates gene expression by triplex formation and recruitment of protein interaction partners. Deleting the triplex motif of endogenous Sarrah in mouse cardiomyocytes augmented apoptosis, showing that triplex formation is of functional relevance for Sarrah action.
Finally, overexpressing Sarrah in an acute myocardial infarction mouse model improved recovery of cardiac contractile function as assessed from ejection fraction, stroke volume, wall motion and wall thickness measured by echocardiography and magnetic resonance imaging. Infarct size was substantially reduced in Sarrah overexpressing mice compared with controls. This in vivo study implies that restoring Sarrah levels in the aged or infarcted heart bears significant therapeutic potential, which can be attributed to the combination of three Sarrah effects: increased cardiomyocytes survival, enhanced contractility of individual cardiomyocytes and paracrine stimulation of endothelial cell proliferation likely contributing to increased angiogenesis and tissue perfusion.
In summary, cardiac lncRNA Sarrah is evolutionary conserved with regard to its genomic locus, function and molecular mechanism. Via triplex formation with gene promoters, it is capable to activate a set of target genes that together mediate the anti-apoptotic and pro-contractile function of Sarrah in cardiomyocytes and that confer angiogenic effects to endothelial cells. A therapeutic utilization of Sarrah in the context of myocardial ischemia is conceivable in the future if Sarrah upregulation proves to be beneficial in further studies.
Identification and characterization of hypoxia-regulated long non-coding RNAs in endothelial cells
(2018)
RNA deep sequencing of the human transcriptome revealed that almost ~84 % of the genome are transcribed, however, only 2 % of all transcripts encode for proteins. All remaining transcripts are referred to as non-coding RNAs and can be divided into small non-coding RNAs (<200 nt) and long non-coding RNAs (lncRNAs; >200 nt). Studies throughout the last decade suggest a broad functional spectrum for lncRNAs. Regarding the cardiovascular field, several studies could show that lncRNAs are implicated in various aspects of endothelial cell biology. The response to hypoxia and the regulation of angiogenesis are key events in the context of several diseases. Therefore, the aim of this study was to determine the influence of hypoxia on lncRNA expression in human umbilical vein endothelial cells and furthermore, to characterize the lncRNA function on a molecular level. ...